Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Recommendation of “Buy” by Analysts

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have earned a consensus recommendation of “Buy” from the ten ratings firms that are covering the firm, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $51.40.

Several research firms have recently commented on DYN. Piper Sandler reissued an “overweight” rating and issued a $53.00 target price on shares of Dyne Therapeutics in a report on Monday, September 23rd. Oppenheimer reaffirmed an “outperform” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. JPMorgan Chase & Co. increased their target price on Dyne Therapeutics from $39.00 to $43.00 and gave the company an “overweight” rating in a research report on Tuesday, July 9th. Guggenheim increased their price objective on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, August 15th. Finally, Stifel Nicolaus boosted their target price on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, August 16th.

Insider Transactions at Dyne Therapeutics

In related news, Director Dirk Kersten sold 2,357 shares of the company’s stock in a transaction dated Wednesday, September 25th. The shares were sold at an average price of $35.06, for a total transaction of $82,636.42. Following the transaction, the director now directly owns 190,939 shares in the company, valued at approximately $6,694,321.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Dirk Kersten sold 2,357 shares of the firm’s stock in a transaction that occurred on Wednesday, September 25th. The stock was sold at an average price of $35.06, for a total transaction of $82,636.42. Following the completion of the sale, the director now directly owns 190,939 shares of the company’s stock, valued at approximately $6,694,321.34. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO John Cox acquired 32,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The shares were acquired at an average price of $33.04 per share, with a total value of $1,057,280.00. Following the acquisition, the chief executive officer now owns 8,000 shares in the company, valued at $264,320. The disclosure for this purchase can be found here. In the last quarter, insiders sold 135,304 shares of company stock worth $4,857,019. 20.77% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Trexquant Investment LP purchased a new stake in shares of Dyne Therapeutics during the fourth quarter worth about $304,000. Rafferty Asset Management LLC increased its holdings in shares of Dyne Therapeutics by 17.7% in the fourth quarter. Rafferty Asset Management LLC now owns 164,041 shares of the company’s stock valued at $2,182,000 after purchasing an additional 24,632 shares during the period. Commodore Capital LP acquired a new stake in shares of Dyne Therapeutics during the fourth quarter worth about $11,970,000. Frazier Life Sciences Management L.P. purchased a new stake in Dyne Therapeutics in the fourth quarter valued at approximately $15,758,000. Finally, Octagon Capital Advisors LP increased its holdings in Dyne Therapeutics by 14.4% in the 4th quarter. Octagon Capital Advisors LP now owns 792,945 shares of the company’s stock worth $10,546,000 after buying an additional 100,000 shares during the period. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Stock Performance

Shares of DYN stock opened at $33.83 on Friday. The stock has a fifty day simple moving average of $40.26 and a two-hundred day simple moving average of $33.84. The firm has a market capitalization of $2.96 billion, a PE ratio of -8.52 and a beta of 1.07. Dyne Therapeutics has a 52-week low of $6.40 and a 52-week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.02. On average, sell-side analysts forecast that Dyne Therapeutics will post -2.96 EPS for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.